208 related articles for article (PubMed ID: 10648391)
1. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse.
Tobal K; Newton J; Macheta M; Chang J; Morgenstern G; Evans PA; Morgan G; Lucas GS; Liu Yin JA
Blood; 2000 Feb; 95(3):815-9. PubMed ID: 10648391
[TBL] [Abstract][Full Text] [Related]
2. Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8; 21).
Tobal K; Yin JA
Blood; 1996 Nov; 88(10):3704-9. PubMed ID: 8916934
[TBL] [Abstract][Full Text] [Related]
3. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia.
Miyamoto T; Nagafuji K; Akashi K; Harada M; Kyo T; Akashi T; Takenaka K; Mizuno S; Gondo H; Okamura T; Dohy H; Niho Y
Blood; 1996 Jun; 87(11):4789-96. PubMed ID: 8639850
[TBL] [Abstract][Full Text] [Related]
4. Real-time quantitative reverse transcription-polymerase chain reaction for the detection of AML1-MTG8 fusion transcripts in t(8;21)-positive acute myelogenous leukemia.
Kondo M; Kudo K; Kimura H; Inaba J; Kato K; Kojima S; Matsuyama T; Horibe K
Leuk Res; 2000 Nov; 24(11):951-6. PubMed ID: 11086178
[TBL] [Abstract][Full Text] [Related]
5. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.
Yin JA; O'Brien MA; Hills RK; Daly SB; Wheatley K; Burnett AK
Blood; 2012 Oct; 120(14):2826-35. PubMed ID: 22875911
[TBL] [Abstract][Full Text] [Related]
6. Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay.
Marcucci G; Livak KJ; Bi W; Strout MP; Bloomfield CD; Caligiuri MA
Leukemia; 1998 Sep; 12(9):1482-9. PubMed ID: 9737700
[TBL] [Abstract][Full Text] [Related]
7. Real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21)-positive AML patients.
Krauter J; Wattjes MP; Nagel S; Heidenreich O; Krug U; Kafert S; Bunjes D; Bergmann L; Ganser A; Heil G
Br J Haematol; 1999 Oct; 107(1):80-5. PubMed ID: 10520027
[TBL] [Abstract][Full Text] [Related]
8. Quantitation of minimal residual disease in t(8;21)-positive acute myelogenous leukemia patients using real-time quantitative RT-PCR.
Sugimoto T; Das H; Imoto S; Murayama T; Gomyo H; Chakraborty S; Taniguchi R; Isobe T; Nakagawa T; Nishimura R; Koizumi T
Am J Hematol; 2000 Jun; 64(2):101-6. PubMed ID: 10814988
[TBL] [Abstract][Full Text] [Related]
9. A quantitative reverse transcriptase polymerase chain reaction method for the detection of leukaemic cells with t(8;21) in peripheral blood.
Fujimaki S; Funato T; Harigae H; Imaizumi M; Suzuki H; Kaneko Y; Miura Y; Sasaki T
Eur J Haematol; 2000 Apr; 64(4):252-8. PubMed ID: 10776697
[TBL] [Abstract][Full Text] [Related]
10. Disappearance of AML1-MTG8 transcript by reverse transcriptase polymerase chain reaction in a patient in remission of acute myeloid leukemia (M2) after low-dose cytosine arabinoside.
Sawada H; Serino Y; Wake A; Yamasaki Y; Izumi Y
Leuk Res; 1998 Sep; 22(9):853-7. PubMed ID: 9716019
[TBL] [Abstract][Full Text] [Related]
11. The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia.
Qin YZ; Wang Y; Xu LP; Zhang XH; Chen H; Han W; Chen YH; Wang FR; Wang JZ; Chen Y; Mo XD; Zhao XS; Chang YJ; Liu KY; Huang XJ
J Hematol Oncol; 2017 Feb; 10(1):44. PubMed ID: 28166825
[TBL] [Abstract][Full Text] [Related]
12. Quantitative nested reverse transcriptase PCR vs. real-time PCR for measuring AML1/ETO (MTG8) transcripts.
Takenokuchi M; Yasuda C; Takeuchi K; Nakamachi Y; Mukai M; Kondo S; Kumagai S; Saigo K; Murayama T; Koizumi T; Tatsumi E
Clin Lab Haematol; 2004 Apr; 26(2):107-14. PubMed ID: 15053804
[TBL] [Abstract][Full Text] [Related]
13. Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia.
Jurlander J; Caligiuri MA; Ruutu T; Baer MR; Strout MP; Oberkircher AR; Hoffmann L; Ball ED; Frei-Lahr DA; Christiansen NP; Block AM; Knuutila S; Herzig GP; Bloomfield CD
Blood; 1996 Sep; 88(6):2183-91. PubMed ID: 8822938
[TBL] [Abstract][Full Text] [Related]
14. Use of the polymerase chain reaction in the detection of AML1/ETO fusion transcript in t(8;21).
Kwong YL; Chan V; Wong KF; Chan TK
Cancer; 1995 Feb; 75(3):821-5. PubMed ID: 7828132
[TBL] [Abstract][Full Text] [Related]
15. Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction.
Kozu T; Miyoshi H; Shimizu K; Maseki N; Kaneko Y; Asou H; Kamada N; Ohki M
Blood; 1993 Aug; 82(4):1270-6. PubMed ID: 8353289
[TBL] [Abstract][Full Text] [Related]
16. AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation.
Kusec R; Laczika K; Knöbl P; Friedl J; Greinix H; Kahls P; Linkesch W; Schwarzinger I; Mitterbauer G; Purtscher B
Leukemia; 1994 May; 8(5):735-9. PubMed ID: 7514242
[TBL] [Abstract][Full Text] [Related]
17. Comparison of nested competitive RT-PCR and real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21) positive acute myelogenous leukemia.
Wattjes MP; Krauter J; Nagel S; Heidenreich O; Ganser A; Heil G
Leukemia; 2000 Feb; 14(2):329-35. PubMed ID: 10673753
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement.
Viehmann S; Teigler-Schlegel A; Bruch J; Langebrake C; Reinhardt D; Harbott J
Leukemia; 2003 Jun; 17(6):1130-6. PubMed ID: 12764380
[TBL] [Abstract][Full Text] [Related]
19. Rapid quantitative detection of TEL-AML1 fusion transcripts in pediatric acute lymphoblastic leukemia by real-time reverse transcription polymerase chain reaction using fluorescently labeled probes.
Bolufer P; Barragán E; Verdeguer A; Cervera J; Fernández JM; Moreno I; Lerma E; Esquembre C; Tasso M; Fuster V; Bermúdez M; Sanz MA
Haematologica; 2002 Jan; 87(1):23-32. PubMed ID: 11801462
[TBL] [Abstract][Full Text] [Related]
20. Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia.
Zhang L; Cao Z; Ruan M; Zeng Q; Zhao L; Li Q; Zou Y; Wang J; Zhu X
Pediatr Blood Cancer; 2014 Oct; 61(10):1761-6. PubMed ID: 24920269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]